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EVIDENCE BASED NEURO-ONCOLOGY
Role of multidisciplinary neuro-oncology tumour boards in cancer management
Mohammad Hamza Bajwa, Saqib Kamran Bakhshi, Muhammad Shahzad Shamim

Abstract
Multidisciplinary care, including a tumour board
discussion for all patients with oncological problems is
now considered a standard. However, this is not uniformly
implemented within many centres, especially in
developing countries. The structure of these tumour
boards allows for comprehensive discussion and debate
regarding various treatment pathways, with inputs from
all specialties. This creates a consensus regarding
management for each patient that is unique and holistic.
Despite its widespread implementation, published data
on neuro-oncology tumour boards is quite limited. The
presented literature review briefly discusses the structure,
goals, outcomes achieved by multidisciplinary tumour
boards within the field of neuro-oncology.
Keywords: Neuro-oncology, Multidisciplinary, Brain
tumour, Tumour board.

Introduction
Management of patients suffering from neurological
malignancies is a multi-disciplinary task, necessitating
important contribution from different stakeholders
including
neurosurgeons,
neurologists,
medical
oncologists, radiation oncologists, neuro-radiologists, and
neuro-pathologists.1 The concept of multi-disciplinary
tumour boards was thus introduced to promote a
coordinated effort from the team of specialists.2,3 Currently,
multidisciplinary cancer care is carried out through two
models: in specialized units/clinics dedicated towards
cancer treatment, as is practiced within Europe, and via
multidisciplinary neuro-oncology tumour boards (NTBs),
that are most frequently used across the globe.2,4 NTBs have
been recognized as the keystone of cancer care by the
European Society of Medical Oncology (ESMO) and the
American Society of Clinical Oncology (ASCO).5 The NTBs
are weekly or fortnightly meetings where all aspects of
patient's pathology, from clinical features to diagnosis,
management and outcomes are discussed, and a consensus
treatment plan is devised.
The benefit of this system lies in its structure. The
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discussions with senior consultants from various
specialties helps reach final diagnosis and evidence-based
treatment options for complex cases. A survey carried out
by ASCO showed that NTBs are used by 85% of the
members surveyed.2 NTBs are not only an essential tool for
assuring patients and their families of the evidence-based
quality care being provided to them, but are also a rich
learning tool for trainees.3,6 That is why, even during the
COVID-19 pandemic, many institutions continued to have
NTBs on digital platforms.7 In this article, we have reviewed
the available literature on NTBs and have discussed their
role in treatment of brain and spine tumours.

Review of Evidence
We searched the literature on PubMed and Google
Scholar. While there were numerous studies on tumour
boards of different specialties, we found very few studies
specific to NTB. In one study published in 2005, Lutterbach
et al., analyzed the work of an interdisciplinary brain
tumour board established at a hospital in Germany comprising of inputs from radiation oncology,
neuropathology, neuro-radiology, neurology, and
neurosurgery (general and stereotactic).8 Over a period of
5 years, they had discussed 1516 patients in 259 meetings.
Analyzing these meetings and recommendations
retrospectively, the study reported that once a
multidisciplinary recommendation was proposed, these
were followed and actualized within 3 months in 91% of
cases. The authors also showed that NTBs showed
particular value in the management of benign skull base
tumours, gliomas and brain metastases. NTB consensus
guidelines were developed by the team for most common
tumour entities, while still being able to provide individual
solutions for special or rare conditions.8
In 2017, Snyder et al., carried out a comprehensive online
cross-sectional survey to look at the role of NTB in neurooncology.1 With the help of Society of Neuro-oncology
and the American Brain Tumour Association, they
collected data from 45 centres, with one respondent from
each centre, belonging to different specialties.1 Almost all
the centres (94%) were of the opinion that tumour boards
played a valuable role in the decision-making process for
patients at their centres.1 Furthermore, these NTBs were
shown to be a pathway for enrolling eligible patients for
novel therapies through clinical trials in 69% of the
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centres.1 On the academic front, 87% of institutions used
tumour boards as a focal point for post-graduate
education of fellows-in-training, residents, and even
medical students.1 An important recommendation from
some centres was to integrate molecular and genetic data
of patients in NTB discussions, or to have a parallel
meeting for it, as molecular features will play a key role in
brain and spine tumour management in the near-future.1
Within this study, the role of neuro-radiologists was also
highlighted. The spectrum of neuro-imaging modalities
(magnetic resonance imaging, positron emission
tomography, and computed tomography) was presented
by a radiologist in 96% of the institutions, neurooncologists in 18%, neurosurgeons in 13%, and radiation
oncologists in 9% of the centres. This emphasises the
increasing complexity of interpreting imaging studies
particularly of neuro-oncology cases with long clinical
courses and several repeat imaging studies done to gauge
treatment response or failure. In fact, dedicated guidelines
for neuro-oncology imaging interpretation and the impact
of treatment modalities on radiological findings requires
dedicated input from experienced neuro-radiologists that
can help guide the rest of the multidisciplinary team.9
In a recent paper published in 2021, Henderson et al.,
described a 'telecollaboration' between neurosurgeons in
Western Kenya with specialists based within the United
States to develop an online NTB.10 They described the
case of a 5-year-old boy who presented with a cystic
enhancing tectal lesion resulting in obstructive
hydrocephalus. However, due to the delicate nature of
the tumour area, the neurosurgeons at the hospital in
Kenya wished to develop a multidisciplinary approach to
this case and requested input from the NTB - to weigh the
risks and benefits of using ventriculoperitoneal shunting
versus endoscopic third ventriculostomy (ETV), and the
timing of surgery as well. This case profile was shared with
US-based physicians through an online e-mail link, and
they responded with recommendations within 12 hours.
Based on their recommendations, the patient underwent
an ETV, and was to be followed up once more with a
paediatric specialist onboard.10 Similarly, there have been
other instances of twinning programmes in neurooncology care where smaller, low-volume centres may
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benefit from the experience of high-volume, academic
centres and discuss their cases at NTBs at these centres.11

Conclusions
According to the limited literature available, NTBs have
been shown to add benefit of review from experts in each
field, guiding holistic patient management. A multimodal
and multidisciplinary treatment strategy can then be
formulated based on that diagnosis, with opinions from
neuro-oncologists and radiation oncologists necessary to
decide between the benefits and risks of chemotherapy,
radiation therapy, and stereotactic radiosurgery.

References
1.

2.

3.
4.

5.
6.

7.

8.

9.

10.

11.

Snyder J, Schultz L, Walbert T. The role of tumour board
conferences in neuro-oncology: a nationwide provider survey. J.
Neurooncol. 2017;133:1-7.
El Saghir NS, Charara RN, Kreidieh FY, Eaton V, Litvin K, Farhat RA,
et al. Global practice and efficiency of multidisciplinary tumour
boards: results of an American Society of Clinical Oncology
international survey. J. Glob. Oncol. 2015;1:57-64.
Barbaro M, Fine HA, Magge RS. Foundations of Neuro-Oncology: A
Multidisciplinary Approach. World Neurosurg. 2021. (online only)
El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L.
Tumour boards: optimizing the structure and improving
efficiency of multidisciplinary management of patients with
cancer worldwide. Am Soc Clin Oncol Educ Book. 2014;34:e461-6.
ASCO-ESMO. ASCO-ESMO consensus statement on quality cancer
care. Ann Oncol. 2006;17:1063-4.
Bernhardt D, Wick W, Weiss SE, Sahgal A, Lo SS, Suh JH, et al.
Neuro-oncology management during the COVID-19 pandemic
with a focus on WHO grades III and IV gliomas. Neuro-Oncol.
2020;22:928-35.
Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ. The multidisciplinary
meeting: an indispensable aid to communication between
different specialities. Eur. J. Cancer. 2006;42:2459-62.
Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, van Velthoven V,
Nikkhah G, et al. The brain tumour board: lessons to be learned
from an interdisciplinary conference. Oncol Res Treat. 2005;28:22-6.
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W,
et al. Immunotherapy response assessment in neuro-oncology:
a report of the RANO working group. Lancet Oncol. 2015;
16:e534-42.
Henderson F, Lepard J, Seibly J, Rambo W, Boswell S, Copeland
WR. An online tumour board with international neurosurgical
collaboration guides surgical decision-making in Western Kenya.
Childs Nerv Syst. 2021;37:715-9.
Gross MW, Läubli H, Cordier D. Multidisciplinary tumour boards as
videoconferences-A new challenge in the COVID-19 era. Ann
Oncol. 2021;32:572-3.

Vol. 71, No. 9, September 2021

